23 May 2013
Keywords: s-p, sugammadex, nda, gets, priority, status, drug
Article | 14 January 2008
US drug major Schering-Plough says that the Food and Drug Administration
has assigned priority review status to the company's New ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
14 January 2008
21 January 2008
22 May 2013
© 2013 thepharmaletter.com